I feel like not much is known about the fact that Cellmid is cooking up a stake in the bone disorder market. (pun intended) We all know about the cancer, fibrotic and inflammatory, and ischemic heart disease pathways of research (Lyramid/Kinera).
But there is more. The bone disorder market is a huge one. The osteoporosis market alone is currently worth around US $9 billion.
https://www.prnewswire.com/news-rel...vartis-merck--co-inc-and-amgen-300454274.html
And Cellmid had a fairly recent patent application in that context. It certainly is more obvious to focus on something that is likely to see clinical trials soon. But do investors realise that IP exists for other important markets, too?
https://patentscope.wipo.int/search...cAn=AU2017050179&queryString=&maxRec=65223986
Anyway, I'm looking forward to 2018 and will likely make this my last post here this year. Happy Holidays everyone.
I feel like not much is known about the fact that Cellmid is...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
-0.001(11.1%) |
Mkt cap ! $3.691M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.9¢ | 0.8¢ | $8.671K | 1.051M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1735002 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 340000 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |